3 British Healthcare Stocks With Revenue Growth Up To 14%

Stubborn US inflation at 3.7% has kept interest rate worries alive and reminded investors how valuable reliable cash flows and essential services can be when prices stay sticky. That puts high quality UK healthcare businesses on many watchlists, as their products and services often link directly to non discretionary demand. This article highlights three leading stocks from a curated British healthcare screener that are worth knowing about now.

The stocks covered below are just a starting sample from the UK healthcare space, and the full screen surfaced 1 more company with an equally compelling story that does not feature in this article. To identify and analyze the highest conviction opportunities right now, move straight into the Best Healthcare Stocks screener.

NIOX Group (AIM:NIOX)

Overview: NIOX Group develops and sells the NIOX VERO portable FeNO testing system, helping clinicians diagnose, monitor and manage asthma and COPD at the point of care.

Operations: NIOX Group generates its £47.5 million in revenue from its NIOX branded respiratory diagnostics products and related consumables.

Market Cap: £285.3 million

NIOX Group provides exposure to a specialised asthma and COPD testing device that fits squarely in healthcare diagnostics, with the 1H 2026 results showing continued use of its point of care platform. The mix of recurring consumables and a focused product line can support specific economics, depending on how one unseen pressure shapes future pricing power.

If that pressure is on your mind, go straight to the 4 key rewards and 1 important warning sign to see how the trade off between opportunity and threat really looks.

HUTCHMED (China) (AIM:HCM)

Overview: HUTCHMED (China) develops targeted oncology drugs like Fruquintinib and Savolitinib, focusing on treating multiple solid tumor cancers globally.

Operations: HUTCHMED generates about $237 million from marketed oncology and immunology products, $245 million from other ventures, and $68 million from R&D, mostly in China.

Market Cap: £1.9 billion

HUTCHMED (China) matters in this Best Healthcare Stocks screen because its cancer franchise links cutting edge targeted treatments directly to real world demand for better outcomes.

"Expansion of approved indications and upcoming NDA submissions for key oncology products (savolitinib and fruquintinib) are expected to contribute to revenue growth, reflecting demand from an aging population and increased chronic disease prevalence in China and globally."

The real watchpoint for investors is how one unresolved pressure ultimately flows through to earnings quality and long term pricing power.

That pressure sits at the center of the full narrative for HUTCHMED (China), where you see how pricing power, partnerships and capital needs could be quietly decoupling beneath the surface.

Integrated Diagnostics Holdings (LSE:IDHC)

Overview: Integrated Diagnostics Holdings runs medical labs and imaging centers across MENA, providing thousands of routine and advanced diagnostic tests that guide treatment decisions.

Operations: Integrated Diagnostics Holdings generates about EGP 2,941 million from walk-in patients and EGP 6,229 million from contract-based diagnostic services, mostly in Egypt.

Market Cap: US$307 million

For the Best Healthcare Stocks theme, Integrated Diagnostics Holdings gives you direct access to everyday clinical testing and radiology services that doctors rely on to make treatment calls, with its footprint across Egypt and the wider MENA region adding an extra layer of healthcare exposure.

"The decision to acquire the remaining 49% stake in the Saudi Arabian venture gives IDH full control over the entity, enabling more flexible execution of its strategy in that market."

The key variable is how changes in funding conditions and capital allocation choices affect future margins.

To see how those funding decisions could accelerate or constrain Integrated Diagnostics Holdings from here, read the full narrative for Integrated Diagnostics Holdings for the full picture on what is really driving returns.

Seeking Alternatives Before The Crowd?

Fresh ideas move first. Screens update, prices shift, and the best setups rarely stay quiet for long. While this data still flies under the radar for now, consider reviewing it promptly.

• Target resilient balance sheets and steady fundamentals by scanning the list of solid balance sheet and fundamentals (9 results) before that quality premium gets fully caught in the wider momentum.
• Hunt for early stage AI momentum by checking the 3 AI small caps while these potential compounders are still dropping in under most investors' filters.
• Position ahead of infrastructure tailwinds by reviewing the 43 power grid technology and infrastructure stocks while capital is still shifting into these essential networks at a measured pace.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com